(Wall Street Journal) – Hims, Keeps and other companies advertise topical finasteride with limited disclosures of side effects

The Food and Drug Administration on Tuesday posted a warning about generic forms of a popular hair-loss medication often sold by major telehealth companies including Hims, Keeps and Ro, citing reports of side effects including sexual dysfunction and suicidal thoughts.

The warning relates to a topical spray form of the drug finasteride, also known by the brand name Propecia. The FDA said it hasn’t approved the sale of those topical forms of the drug, or any safety information related to them. Only the pill version is FDA-approved. (Read More)